These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 1786929)

  • 21. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
    Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
    J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
    Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y
    Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of cholesterol biosynthesis in primary cultured rat hepatocytes by artichoke (Cynara scolymus L.) extracts.
    Gebhardt R
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1122-8. PubMed ID: 9732368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concentration and distribution of ubiquinone (coenzyme Q), the endogenous lipid antioxidant, in the rat lens: effect of treatment with simvastatin.
    Cenedella RJ; Neely AR; Sexton P
    Mol Vis; 2005 Aug; 11():594-602. PubMed ID: 16110301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
    J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Source of cholesterol for the ocular lens, studied with U18666A: a cataract-producing inhibitor of lipid metabolism.
    Cenedella RJ
    Exp Eye Res; 1983 Jul; 37(1):33-43. PubMed ID: 6873203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in Chbb: Thom rats.
    Cenedella RJ; Kuszak JR; Al-Ghoul KJ; Qin S; Sexton PS
    J Lipid Res; 2003 Jan; 44(1):198-211. PubMed ID: 12518039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Could cholesterol-lowering drugs cause cataracts?
    Harv Mens Health Watch; 2014 Jan; 18(6):8. PubMed ID: 24683611
    [No Abstract]   [Full Text] [Related]  

  • 30. The toxicity of a fluorinated-biphenyl HMG-CoA reductase inhibitor in beagle dogs.
    Gerson RJ; Allen HL; Lankas GR; MacDonald JS; Alberts AW; Bokelman DL
    Fundam Appl Toxicol; 1991 Feb; 16(2):320-9. PubMed ID: 2055362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of cataract production by 3-beta(2-diethylaminoethoxy) androst-5-en-17-one hydrochloride, U18666A: an inhibitor of cholesterol biosynthesis.
    Cenedella RJ; Bierkamper GG
    Exp Eye Res; 1979 Jun; 28(6):673-88. PubMed ID: 467524
    [No Abstract]   [Full Text] [Related]  

  • 32. Induction of cataracts in the rat by derivatives of (4' -pyridyl) - 1 piperazine.
    Lapalus P; Luyckx J
    Toxicol Eur Res; 1979 Mar; 2(2):99-102. PubMed ID: 505449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypolipidemic activity and toxicity studies of a styrl-hexahydroindolinol, 34-250.
    Bagdon RE; Engstrom RG; Kelly LA; Hartman HA; Robison RL; Visscher GE
    Toxicol Appl Pharmacol; 1983 Jun; 69(1):12-28. PubMed ID: 6857683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitors of cholesterol synthesis and cataracts.
    Cenedella RJ
    JAMA; 1987 Mar; 257(12):1602. PubMed ID: 3644022
    [No Abstract]   [Full Text] [Related]  

  • 35. Inhibition of cholesterol synthesis.
    Kritchevsky D
    J Nutr; 1987 Jul; 117(7):1330-4. PubMed ID: 3612311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct perturbation of lens membrane structure may contribute to cataracts caused by U18666A, an oxidosqualene cyclase inhibitor.
    Cenedella RJ; Jacob R; Borchman D; Tang D; Neely AR; Samadi A; Mason RP; Sexton P
    J Lipid Res; 2004 Jul; 45(7):1232-41. PubMed ID: 15102886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Research relating the use of systematic drug and cataracts].
    Lei JY; Yao K
    Zhonghua Yan Ke Za Zhi; 2013 May; 49(5):468-71. PubMed ID: 24021188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sterol synthesis by the ocular lens of the rat during postnatal development.
    Cenedella RJ
    J Lipid Res; 1982 May; 23(4):619-26. PubMed ID: 6808071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholesterol and cataracts.
    Cenedella RJ
    Surv Ophthalmol; 1996; 40(4):320-37. PubMed ID: 8658343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cataracts in dogs following subchronic administration of the phenylpiperazine antihypertensive agent PD 78787.
    Susick RL; Jordan RA; Watkins JR
    Fundam Appl Toxicol; 1991 Oct; 17(3):593-600. PubMed ID: 1794661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.